

# Robust Control of Biological Models

*Application to the combined therapy of cancer*

Mazen Alamir

French National Research Center (CNRS)  
Gipsa-lab, Control Systems Department.  
University of Grenoble, France




**GRENOBLE**  
UNIVERSITÉS

## Did you say, Grenoble ?



## Did you say, Grenoble ?



But also,

- Second French Scientific Pole (after Paris)
- First in Information Science
- Administered by Joseph Fourier
- 1 Nobel Price (Louis Néel)
- 1 Turing Price (Joseph Sifakis)
- Worldwide center in NanoTechnologies
- Winter Olympic Games (1968)
- Starting point for the French Revolution
- European Hub for Green Energy (KIC)
- Elected preferred French city to study in by students (2010)
- 70,000 students

Biological Models & The Uncertainty Issue

Control-Related Paradigms in Systems Biology


New Control Paradigms in Cancer Therapy

The Hamilton-Jacobi-Isaacs PDE

Robust Combined Therapy Under Drug Limitation

Conclusion & Future Work

- We need models to
  - understand,
  - predict or to
  - decide how to act
 on a given biological system.



$$\frac{dT}{dt} = aT(1 - bT) - cNT - DT - K_T(1 - e^{-M})T, \quad (1)$$

$$\frac{dN}{dt} = cC - fN + g\frac{T^2}{h + T^2}N - pNT - K_N(1 - e^{-M})N, \quad (2)$$

$$\frac{dL}{dt} = -mL + j\frac{D^2T^2}{k + D^2T^2}L - qLT + (r_1N + r_2C)T - uNL^2 - K_L(1 - e^{-M})L + \frac{p_I I}{g_I + I}L + v_L(t), \quad (3)$$

$$\frac{dC}{dt} = \alpha - \beta C - K_C(1 - e^{-M})C, \quad (4)$$

$$\frac{dM}{dt} = -\gamma M + v_M(t), \quad (5)$$

$$\frac{dI}{dt} = -\mu_I I + v_I(t) \quad (6)$$

$$D = d\frac{(L/T)^l}{s + (L/T)^l} \quad (7)$$

*DePillis et al.*

Mixed immunotherapy and chemotherapy of tumors . . .

*Journal of Theoretical Biology, (61), 2005.*

- We need models to
  - understand,
  - predict or to
  - decide how to act
 on a given biological system.

$$\mathcal{P}_1 : \min_{v_M(\cdot), v_L(\cdot), v_I(\cdot)} T(t_f)$$

under  $C(t) \geq C_{min}, \quad \forall t \in [0, t_f]$ .

S. Chareyron & M. Alamir

Journal of Theoretical Biology, (258), 2009.

$$\frac{dT}{dt} = aT(1 - bT) - cNT - DT - K_T(1 - e^{-M})T, \quad (1)$$

$$\frac{dN}{dt} = cC - fN + g \frac{T^2}{h + T^2} N - pNT - K_N(1 - e^{-M})N, \quad (2)$$

$$\frac{dL}{dt} = -mL + j \frac{D^2 T^2}{k + D^2 T^2} L - qLT + (r_1 N + r_2 C)T - uNL^2 - K_L(1 - e^{-M})L + \frac{p_I I}{g_I + I} L + v_L(t), \quad (3)$$

$$\frac{dC}{dt} = \alpha - \beta C - K_C(1 - e^{-M})C, \quad (4)$$

$$\frac{dM}{dt} = -\gamma M + v_M(t), \quad (5)$$

$$\frac{dI}{dt} = -\mu_I I + v_I(t) \quad (6)$$

$$D = d \frac{(L/T)^l}{s + (L/T)^l} \quad (7)$$

DePillis et al.

Mixed immunotherapy and chemotherapy of tumors ...

Journal of Theoretical Biology, (61), 2005.

- We need models to
  - understand,
  - predict or to
  - decide how to act
 on a given biological system.

$$\mathcal{P}_2 : \max_{v_M(\cdot), v_L(\cdot), v_I(\cdot)} \min_{t \in [0, t_f]} C(t)$$

under  $T(t_f) \leq \gamma T(0)$  with  $\gamma \in ]0, 1[$ .

*S. Chareyron & M. Alamir*

*Journal of Theoretical Biology, (258), 2009.*

$$\frac{dT}{dt} = aT(1 - bT) - cNT - DT - K_T(1 - e^{-M})T, \quad (1)$$

$$\frac{dN}{dt} = cC - fN + g \frac{T^2}{h + T^2} N - pNT - K_N(1 - e^{-M})N, \quad (2)$$

$$\frac{dL}{dt} = -mL + j \frac{D^2 T^2}{k + D^2 T^2} L - qLT + (r_1 N + r_2 C)T - uNL^2 - K_L(1 - e^{-M})L + \frac{p_I I}{g_I + I} L + v_L(t), \quad (3)$$

$$\frac{dC}{dt} = \alpha - \beta C - K_C(1 - e^{-M})C, \quad (4)$$

$$\frac{dM}{dt} = -\gamma M + v_M(t), \quad (5)$$

$$\frac{dI}{dt} = -\mu_I I + v_I(t) \quad (6)$$


$$D = d \frac{(L/T)^l}{s + (L/T)^l} \quad (7)$$

*DePillis et al.*

Mixed immunotherapy and chemotherapy of tumors ...

*Journal of Theoretical Biology, (61), 2005.*

- We need models to
  - understand,
  - predict or to
  - decide how to act
 on a given biological system.



S. Chareyron & M. Alamir

Journal of Theoretical Biology, (258), 2009.

$$\frac{dT}{dt} = aT(1 - bT) - cNT - DT - K_T(1 - e^{-M})T, \quad (1)$$

$$\frac{dN}{dt} = cC - fN + g \frac{T^2}{h + T^2} N - pNT - K_N(1 - e^{-M})N, \quad (2)$$

$$\frac{dL}{dt} = -mL + j \frac{D^2 T^2}{k + D^2 T^2} L - qLT + (r_1 N + r_2 C)T - uNL^2 - K_L(1 - e^{-M})L + \frac{p_I I}{g_I + I} L + v_L(t), \quad (3)$$

$$\frac{dC}{dt} = \alpha - \beta C - K_C(1 - e^{-M})C, \quad (4)$$

$$\frac{dM}{dt} = -\gamma M + v_M(t), \quad (5)$$

$$\frac{dI}{dt} = -\mu_I I + v_I(t) \quad (6)$$

$$D = d \frac{(L/T)^l}{s + (L/T)^l} \quad (7)$$

DePillis et al.

Mixed immunotherapy and chemotherapy of tumors ...

Journal of Theoretical Biology, (61), 2005.

- We need models to
  - understand,
  - predict or to
  - decide how to act
 on a given biological system.
- Such models generally involve many parameters that are
  - unknown and
  - time-varying

$$\frac{dT}{dt} = aT(1 - bT) - cNT - DT - K_T(1 - e^{-M})T, \quad (1)$$

$$\frac{dN}{dt} = cC - fN + g\frac{T^2}{h + T^2}N - pNT - K_N(1 - e^{-M})N, \quad (2)$$

$$\frac{dL}{dt} = -mL + j\frac{D^2T^2}{k + D^2T^2}L - qLT + (r_1N + r_2C)T - uNL^2 - K_L(1 - e^{-M})L + \frac{p_I I}{g_I + I}L + v_L(t), \quad (3)$$

$$\frac{dC}{dt} = \alpha - \beta C - K_C(1 - e^{-M})C, \quad (4)$$

$$\frac{dM}{dt} = -\gamma M + v_M(t), \quad (5)$$

$$\frac{dI}{dt} = -\mu_I I + v_I(t) \quad (6)$$

$$D = d\frac{(L/T)^l}{s + (L/T)^l} \quad (7)$$

*DePillis et al.*

Mixed immunotherapy and chemotherapy of tumors ...

*Journal of Theoretical Biology, (61), 2005.*

- We need models to
  - understand,
  - predict or to
  - decide how to act
 on a given biological system.
- Such models generally involve many parameters that are
  - unknown and
  - time-varying
- These model discrepancies can strongly question the nominal assertions.

$$\frac{dT}{dt} = aT(1 - bT) - cNT - DT - K_T(1 - e^{-M})T, \quad (1)$$

$$\frac{dN}{dt} = cC - fN + g\frac{T^2}{h + T^2}N - pNT - K_N(1 - e^{-M})N, \quad (2)$$

$$\frac{dL}{dt} = -mL + j\frac{D^2T^2}{k + D^2T^2}L - qLT + (r_1N + r_2C)T - uNL^2 - K_L(1 - e^{-M})L + \frac{p_I I}{g_I + I}L + v_L(t), \quad (3)$$

$$\frac{dC}{dt} = \alpha - \beta C - K_C(1 - e^{-M})C, \quad (4)$$

$$\frac{dM}{dt} = -\gamma M + v_M(t), \quad (5)$$

$$\frac{dI}{dt} = -\mu_I I + v_I(t) \quad (6)$$

$$D = d\frac{(L/T)^l}{s + (L/T)^l} \quad (7)$$

*DePillis et al.*

Mixed immunotherapy and chemotherapy of tumors ...

**Journal of Theoretical Biology, (61), 2005.**

- We need models to
  - understand,
  - predict or to
  - decide how to act
 on a given biological system.
- Such models generally involve many parameters that are
  - unknown and
  - time-varying
- These model discrepancies can strongly question the nominal assertions.
- This robustness issue is rarely addressed in the systems biology related literature

$$\frac{dT}{dt} = aT(1 - bT) - cNT - DT - K_T(1 - e^{-M})T, \quad (1)$$

$$\frac{dN}{dt} = cC - fN + g\frac{T^2}{h + T^2}N - pNT - K_N(1 - e^{-M})N, \quad (2)$$

$$\frac{dL}{dt} = -mL + j\frac{D^2T^2}{k + D^2T^2}L - qLT + (r_1N + r_2C)T - uNL^2 - K_L(1 - e^{-M})L + \frac{p_I I}{g_I + I}L + v_L(t), \quad (3)$$

$$\frac{dC}{dt} = \alpha - \beta C - K_C(1 - e^{-M})C, \quad (4)$$

$$\frac{dM}{dt} = -\gamma M + v_M(t), \quad (5)$$

$$\frac{dI}{dt} = -\mu_I I + v_I(t) \quad (6)$$

$$D = d\frac{(L/T)^l}{s + (L/T)^l} \quad (7)$$

*DePillis et al.*

Mixed immunotherapy and chemotherapy of tumors ...

*Journal of Theoretical Biology, (61), 2005.*

## Control-Related Paradigms in Systems Biology

$$\dot{p} = -w_1 p \ln\left(\frac{p}{q}\right) - w_2 p v_2$$

$$\dot{q} = w_3 p - (w_4 + w_5 p^{\frac{2}{3}})q - w_6 v_1 q$$

$$\dot{y}_1 = v_1$$

$$\dot{y}_2 = v_2$$

*Hahnfeldt et al.* Tumor development under angiogenic signaling: ...

*Cancer Research*, (59), 1999.

- $p$  tumor cells population level
- $q$  vasculature level
- $v_1$  Anti-angiogenic drug
- $v_2$  Chemotherapy drug
- $y_1, y_2$  Already injected drug
- $w \in \mathbb{R}^6$  model parameters

Consider a biological model:

$$\dot{x} = f(x, u, w)$$

- $x \in \mathbb{R}^n$  (state)
- $u \in \mathbb{U} \subset \mathbb{R}^{n_u}$  (Control input)
- $w \in \mathbb{W} \subset \mathbb{R}^{n_w}$  (Disturbance)

typically

$$\mathbb{W} := \left\{ w \mid w_i = w_i^{nom}(1 + \eta_i) \right\}$$

Example of control formulation

$$\min_{u(\cdot)} [p(T)] \quad \text{under } y_i(T) \leq y_i^{max}$$

$$\begin{aligned} \dot{p} &= -w_1 p \ln\left(\frac{p}{q}\right) - w_2 p v_2 \\ \dot{q} &= w_3 p - (w_4 + w_5 p^{\frac{2}{3}})q - w_6 v_1 q \\ \dot{y}_1 &= v_1 \\ \dot{y}_2 &= v_2 \end{aligned}$$

*Hahnfeldt et al.* Tumor development under angiogenic signaling: ...

**Cancer Research**, (59), 1999.

- $p$  tumor cells population level
- $q$  vasculature level
- $v_1$  Anti-angiogenic drug
- $v_2$  Chemotherapy drug
- $y_1, y_2$  Already injected drug
- $w \in \mathbb{R}^6$  model parameters

## Optimal Control Paradigm

$$\dot{x} = f(x, u, w^{nom}) \text{ under } u \in \mathcal{U}$$

$$\min_{u(\cdot)} [p(T)] \text{ under } y_i(T) \leq y_i^{max}$$

- Existence of optimal solutions
- Pontryagin Maximum Principle
- Investigate the structure of optimal control profiles  $u^{opt}(\cdot)$

△ *Ledzewics, IEEE CDC, 2008.*

△ *Swan, IMA J. of Math. Appl. in Medicine and Biology, 1988.*

△ *DePillis and Radunskaya, J. Theoretical Medicine, (3), 2005.*

△ *Alamir and Chareyron, Optimal Control Applications and Methods, 2007*

$$\begin{aligned} \dot{p} &= -w_1 p \ln\left(\frac{p}{q}\right) - w_2 p v_2 \\ \dot{q} &= w_3 p - (w_4 + w_5 p^{\frac{2}{3}})q - w_6 v_1 q \\ \dot{y}_1 &= v_1 \\ \dot{y}_2 &= v_2 \end{aligned}$$

*Hahnfeldt et al. Tumor development under angiogenic signaling: ...*

*Cancer Research, (59), 1999.*

- $p$  tumor cells population level
- $q$  vasculature level
- $u_1$  Anti-angiogenic drug
- $v_1$  Chemotherapy drug
- $v_2, y_2$  Already injected drug
- $w \in \mathbb{R}^6$  model parameters

## Optimal Control Paradigm

$$\dot{x} = f(x, u, w^{nom}) \text{ under } u \in \mathbb{U}$$

$$\min_{u(\cdot)} [p(T)] \text{ under } y_i(T) \leq y_i^{max}$$

Unfortunately,

- $w^{nom}$  is not constant
- hard to determine
- High sensitivity may arise

$$\begin{aligned} \dot{p} &= -w_1 p \ln\left(\frac{p}{q}\right) - w_2 p v_2 \\ \dot{q} &= w_3 p - (w_4 + w_5 p^{\frac{2}{3}})q - w_6 v_1 q \\ \dot{y}_1 &= v_1 \\ \dot{y}_2 &= v_2 \end{aligned}$$

*Hahnfeldt et al.* Tumor development under angiogenic signaling: ...

**Cancer Research**, (59), 1999.

- $p$  tumor cells population level
- $q$  vasculature level
- $u_1$  Anti-angiogenic drug
- $v_1$  Chemotherapy drug
- $v_2, y_2$  Already injected drug
- $w \in \mathbb{R}^6$  model parameters


## Optimal Control Paradigm

$$\dot{x} = f(x, u, w^{nom}) \text{ under } u \in \mathbb{U}$$

$$\min_{u(\cdot)} [p(T)] \text{ under } y_i(T) \leq y_i^{max}$$

Unfortunately,

- $w^{nom}$  is not constant
- hard to determine
- High sensitivity may arise



$$\begin{aligned} \dot{p} &= -w_1 p \ln\left(\frac{p}{q}\right) - w_2 p v_2 \\ \dot{q} &= w_3 p - (w_4 + w_5 p^{\frac{2}{3}})q - w_6 v_1 q \\ \dot{y}_1 &= v_1 \\ \dot{y}_2 &= v_2 \end{aligned}$$

*Hahnfeldt et al.* Tumor development under angiogenic signaling: ...

*Cancer Research*, (59), 1999.

- $p$  tumor cells population level
- $q$  vasculature level
- $u_1$  Anti-angiogenic drug
- $v_1$  Chemotherapy drug
- $v_2, y_2$  Already injected drug
- $w \in \mathbb{R}^6$  model parameters


## Optimal Control Paradigm

$$\dot{x} = f(x, u, w^{nom}) \text{ under } u \in \mathbb{U}$$

$$\min_{u(\cdot)} [p(T)] \text{ under } y_i(T) \leq y_i^{max}$$

Unfortunately,

- $w^{nom}$  is not constant
- hard to determine
- High sensitivity may arise



$$\begin{aligned} \dot{p} &= -w_1 p \ln\left(\frac{p}{q}\right) - w_2 p v_2 \\ \dot{q} &= w_3 p - (w_4 + w_5 p^{\frac{2}{3}})q - w_6 v_1 q \\ \dot{y}_1 &= v_1 \\ \dot{y}_2 &= v_2 \end{aligned}$$

*Hahnfeldt et al.* Tumor development under angiogenic signaling: ...

**Cancer Research**, (59), 1999.

- $p$  tumor cells population level
- $q$  vasculature level
- $u_1$  Anti-angiogenic drug
- $v_1$  Chemotherapy drug
- $v_2, y_2$  Already injected drug
- $w \in \mathbb{R}^6$  model parameters


## Optimal Control Paradigm

$$\dot{x} = f(x, u, w^{nom}) \text{ under } u \in \mathbb{U}$$

$$\min_{u(\cdot)} [p(T)] \text{ under } y_i(T) \leq y_i^{max}$$

Unfortunately,

- $w^{nom}$  is not constant
- hard to determine
- High sensitivity may arise



$$\begin{aligned} \dot{p} &= -w_1 p \ln\left(\frac{p}{q}\right) - w_2 p v_2 \\ \dot{q} &= w_3 p - (w_4 + w_5 p^{\frac{2}{3}})q - w_6 v_1 q \\ \dot{y}_1 &= v_1 \\ \dot{y}_2 &= v_2 \end{aligned}$$

*Hahnfeldt et al.* Tumor development under angiogenic signaling: ...

*Cancer Research*, (59), 1999.

- $p$  tumor cells population level
- $q$  vasculature level
- $u_1$  Anti-angiogenic drug
- $v_1$  Chemotherapy drug
- $v_2, y_2$  Already injected drug
- $w \in \mathbb{R}^6$  model parameters


## Optimal Control Paradigm

$$\dot{x} = f(x, u, w^{nom}) \text{ under } u \in \mathbb{U}$$

$$\min_{u(\cdot)} [p(T)] \text{ under } y_i(T) \leq y_i^{max}$$

Unfortunately,

- $w^{nom}$  is not constant
- hard to determine
- High sensitivity may arise



$$\begin{aligned} \dot{p} &= -w_1 p \ln\left(\frac{p}{q}\right) - w_2 p v_2 \\ \dot{q} &= w_3 p - (w_4 + w_5 p^{\frac{2}{3}})q - w_6 v_1 q \\ \dot{y}_1 &= v_1 \\ \dot{y}_2 &= v_2 \end{aligned}$$

*Hahnfeldt et al.* Tumor development under angiogenic signaling: ...

**Cancer Research**, (59), 1999.

- $p$  tumor cells population level
- $q$  vasculature level
- $u_1$  Anti-angiogenic drug
- $v_1$  Chemotherapy drug
- $v_2, y_2$  Already injected drug
- $w \in \mathbb{R}^6$  model parameters


## Optimal Control Paradigm

$$\dot{x} = f(x, u, w^{nom}) \text{ under } u \in \mathbb{U}$$

$$\min_{u(\cdot)} [p(T)] \text{ under } y_i(T) \leq y_i^{max}$$

Unfortunately,

- $w^{nom}$  is not constant
- hard to determine
- High sensitivity may arise



## Sensitivity Analysis Paradigm

Evaluate the sensitivity indicator of the nominally optimal solution:

$$\frac{\partial p^{opt}(T)}{\partial w}(x_0, w^{nom})$$

- For a specific initial state  $x_0$
- Involved computation for a non constant  $w(\cdot)$
- Local results

*K. L. Kiran & S. Lakshminarayanan, Global Sensitivity Analysis and Model-Based Reactive Scheduling of Targeted Cancer Immunotherapy. **BioSystems**, (101), 2010.*


## Optimal Control Paradigm

$$\dot{x} = f(x, u, w^{nom}) \text{ under } u \in \mathbb{U}$$

$$\min_{u(\cdot)} [p(T)] \text{ under } y_i(T) \leq y_i^{max}$$

Unfortunately,

- $w^{nom}$  is not constant
- hard to determine
- High sensitivity may arise



## Feedback Control Paradigm

- 1 At decision instant  $t_k$ , solve the optimal control problem to obtain  $u^{opt}(\cdot, x(t_k))$  defined on  $[t_k, T]$ .
- 2 Apply  $u^{opt}(t, x(t_k))$  for  $t \in [t_k, t_{k+1}]$
- 3 measure the state at  $t_{k+1}$ ,
- 4  $k \leftarrow k + 1$ . Goto step 1


## Optimal Control Paradigm

$$\dot{x} = f(x, u, w^{nom}) \text{ under } u \in \mathbb{U}$$

$$\min_{u(\cdot)} [p(T)] \text{ under } y_i(T) \leq y_i^{max}$$

Unfortunately,

- $w^{nom}$  is not constant
- hard to determine
- High sensitivity may arise



## Feedback Control Paradigm

- 1 At decision instant  $t_k$ , solve the optimal control problem to obtain  $u^{opt}(\cdot, x(t_k))$  defined on  $[t_k, T]$ .
- 2 Apply  $u^{opt}(t, x(t_k))$  for  $t \in [t_k, t_{k+1}]$
- 3 measure the state at  $t_{k+1}$ ,
- 4  $k \leftarrow k + 1$ . Goto step 1

This partially corrects the disturbance induced discrepancy over the duration of the therapy


## Optimal Control Paradigm

$$\dot{x} = f(x, u, w^{nom}) \text{ under } u \in \mathbb{U}$$

$$\min_{u(\cdot)} [p(T)] \text{ under } y_i(T) \leq y_i^{max}$$

Unfortunately,

- $w^{nom}$  is not constant
- hard to determine
- High sensitivity may arise



## Feedback Control Paradigm

- 1 At decision instant  $t_k$ , solve the optimal control problem to obtain  $u^{opt}(\cdot, x(t_k))$  defined on  $[t_k, T]$ .
- 2 Apply  $u^{opt}(t, x(t_k))$  for  $t \in [t_k, t_{k+1}]$
- 3 measure the state at  $t_{k+1}$ ,
- 4  $k \leftarrow k + 1$ . Goto step 1

This is Model Predictive Control

Florian et al. *J. Computers in Biology and Medicine*, (38), 2008.

S. Chareyron & M. Alamir  
*Journal of Theoretical Biology*, (258), 2009.

## On-line Parameter Estimation

**Irrelevant** because of the lack of excitation needed to identify the high number of parameters.

## Feedback Control Paradigm

- ① At decision instant  $t_k$ , solve the optimal control problem to obtain  $u^{opt}(\cdot, x(t_k))$  defined on  $[t_k, T]$ .
- ② Apply  $u^{opt}(t, x(t_k))$  for  $t \in [t_k, t_{k+1}]$
- ③ measure the state at  $t_{k+1}$ ,
- ④  $k \leftarrow k + 1$ . Goto step 1

This is Model Predictive Control

*Florian et al. J. Computers in Biology and Medicine, (38), 2008.*

*S. Chareyron & M. Alamir  
Journal of Theoretical Biology, (258), 2009.*

## Guaranteed Contraction Map

### Given

- A subset of initial state  $\mathbb{X}$
- A subset of admissible parameter set  $\mathbb{W}$
- A therapy duration  $T$
- Allowable drug quantities  $y_i^{max}$

### Compute


the Guaranteed Contraction Map (GCM) and the associated feedback control

$$u = K(t, x) \quad ; \quad t \in [0, T]$$

$$\begin{aligned} \dot{p} &= -w_1 p \ln\left(\frac{p}{q}\right) - w_2 p v_2 \\ \dot{q} &= w_3 p - (w_4 + w_5 p^{\frac{2}{3}})q - w_6 v_1 q \\ \dot{y}_1 &= v_1 \\ \dot{y}_2 &= v_2 \end{aligned}$$

*Hahnfeldt et al.* Tumor development under angiogenic signaling: ...

*Cancer Research*, (59), 1999.



## Guaranteed Contraction Map

### Given

- A subset of initial state  $\mathbb{X}$
- A subset of admissible parameter set  $\mathbb{W}$
- A therapy duration  $T$
- Allowable drug quantities  $y_i^{max}$

### Compute


the Guaranteed Contraction Map (GCM) and the associated feedback control

$$u = K(t, x) \quad ; \quad t \in [0, T]$$

$$\begin{aligned} \dot{p} &= -w_1 p \ln\left(\frac{p}{q}\right) - w_2 p v_2 \\ \dot{q} &= w_3 p - (w_4 + w_5 p^{\frac{2}{3}})q - w_6 v_1 q \\ \dot{y}_1 &= v_1 \\ \dot{y}_2 &= v_2 \end{aligned}$$

*Hahnfeldt et al.* Tumor development under angiogenic signaling: ...

*Cancer Research*, (59), 1999.



## Necessary Drug Quantity

### Given

- An initial state  $x_0 \in \mathbb{X}$
- A subset of admissible parameter set  $\mathbb{W}$
- A targeted contraction ratio

$$\gamma := \frac{p(T)}{p(0)} < 1$$

### Compute

- The Feasibility
- The therapy duration  $T$
- The quantity of drugs  $y_i^{max}$  needed
- The feedback  $K(t, x)$

$$\begin{aligned}\dot{p} &= -w_1 p \ln\left(\frac{p}{q}\right) - w_2 p v_2 \\ \dot{q} &= w_3 p - (w_4 + w_5 p^{\frac{2}{3}})q - w_6 v_1 q \\ \dot{y}_1 &= v_1 \\ \dot{y}_2 &= v_2\end{aligned}$$

*Hahnfeldt et al.* Tumor development under angiogenic signaling: ...

*Cancer Research*, (59), 1999.

- $p$  tumor cells population level
- $q$  vasculature level
- $u_1$  Anti-angiogenic drug
- $v_1$  Chemotherapy drug
- $v_2, y_2$  Already injected drug
- $w \in \mathbb{R}^6$  model parameters

- Robust Control Design:

## The **Hamilton-Jacobi-Isaacs** (HJI) PDE's

- Computational Framework
- Application to the combined Therapy  
(Chemotherapy/Anti-angiogenic)
- Preliminary Results
- Future Work (Research Proposal)

## System Model

$$\dot{x} = f(x, u, w)$$

## Cost Function

$$J := \Psi(x(T)) + \int_t^T L(x(\tau), u(\tau), w(\tau)) d\tau$$

---

$$\frac{\partial V}{\partial t}(t, x) + \hat{H}\left(x, \frac{\partial V}{\partial x}(t, x)\right) = 0 \quad ; \quad V(T, x) = \Psi(x)$$

---

- $H(x, \lambda, u, w) = L(x, u, w) + \lambda^T f(x, u, w)$
- $\hat{H}(x, \lambda) := \min_{u \in \mathbb{U}(x)} \left[ \max_{w \in \mathbb{W}(x)} H(x, \lambda, u, w) \right]$

**Theorem 1** (Isaacs verification theorem). If  $V(t, x)$  is a function of class  $C^1$  in  $t$  and  $x$  that satisfies the following Hamilton Jacobi Equation with boundary condition:

$$V_t + \hat{H}(x, V_x, t) = 0, \quad V(T, x) = \Psi(x), \quad (7)$$

where  $\hat{H}$  is given by (6), then the control strategy

$$u(\tau, x(\tau)) = \hat{u}(x(\tau), V_x(\tau, x(\tau)), \tau) \quad \tau \in [t, T] \quad (8)$$

is an optimal solution for problem (3). Furthermore, the corresponding optimal value is exactly  $V(t, x(t))$ .

*Isaacs, R.*

Differential Games

**RAND Corporation Research**

**Memorandum, (1954)**

*Başar T. and Olsder G. J.*

Dynamic Non Cooperative Game

**Theory. NY, Academic Press, (1982)**

$$V(t, x(t)) := \min_{u(\cdot)} \left[ \max_{w(\cdot)} \left[ \Psi(x(T)) + \int_t^T L(x(\tau), u(\tau), w(\tau)) d\tau \right] \right] \quad (3)$$


**Theorem 1** (Isaacs verification theorem). If  $V(t, x)$  is a function of class  $C^1$  in  $t$  and  $x$  that satisfies the following Hamilton Jacobi Equation with boundary condition:

$$V_t + \hat{H}(x, V_x, t) = 0, \quad V(T, x) = \Psi(x), \quad (7)$$

where  $\hat{H}$  is given by (6), then the control strategy

$$u(\tau, x(\tau)) = \hat{u}(x(\tau), V_x(\tau, x(\tau)), \tau) \quad \tau \in [t, T] \quad (8)$$

is an optimal solution for problem (3). Furthermore, the corresponding optimal value is exactly  $V(t, x(t))$ .



$$V(t, x(t)) := \min_{u(\cdot)} \left[ \max_{w(\cdot)} \left[ \Psi(x(T)) + \int_t^T L(x(\tau), u(\tau), w(\tau)) d\tau \right] \right] \quad (3)$$


**Theorem 1** (Isaacs verification theorem). If  $V(t, x)$  is a function of class  $C^1$  in  $t$  and  $x$  that satisfies the following Hamilton Jacobi Equation with boundary condition:

$$V_t + \hat{H}(x, V_x, t) = 0, \quad V(T, x) = \Psi(x), \quad (7)$$

where  $\hat{H}$  is given by (6), then the control strategy

$$u(\tau, x(\tau)) = \hat{u}(x(\tau), V_x(\tau, x(\tau)), \tau) \quad \tau \in [t, T] \quad (8)$$

is an optimal solution for problem (3). Furthermore, the corresponding optimal value is exactly  $V(t, x(t))$ .



$$V(t, x(t)) := \min_{u(\cdot)} \left[ \max_{w(\cdot)} \left[ \Psi(x(T)) + \int_t^T L(x(\tau), u(\tau), w(\tau)) d\tau \right] \right] \quad (3)$$


**Theorem 1** (Isaacs verification theorem). If  $V(t, x)$  is a function of class  $C^1$  in  $t$  and  $x$  that satisfies the following Hamilton Jacobi Equation with boundary condition:

$$V_t + \hat{H}(x, V_x, t) = 0, \quad V(T, x) = \Psi(x), \quad (7)$$

where  $\hat{H}$  is given by (6), then the control strategy

$$u(\tau, x(\tau)) = \hat{u}(x(\tau), V_x(\tau, x(\tau)), \tau) \quad \tau \in [t, T] \quad (8)$$

is an optimal solution for problem (3). Furthermore, the corresponding optimal value is exactly  $V(t, x(t))$ .



$$V(t, x(t)) := \min_{u(\cdot)} \left[ \max_{w(\cdot)} \left[ \Psi(x(T)) + \int_t^T L(x(\tau), u(\tau), w(\tau)) d\tau \right] \right] \quad (3)$$


**Theorem 1** (Isaacs verification theorem). If  $V(t, x)$  is a function of class  $C^1$  in  $t$  and  $x$  that satisfies the following Hamilton Jacobi Equation with boundary condition:

$$V_t + \hat{H}(x, V_x, t) = 0, \quad V(T, x) = \Psi(x), \quad (7)$$

where  $\hat{H}$  is given by (6), then the control strategy

$$u(\tau, x(\tau)) = \hat{u}(x(\tau), V_x(\tau, x(\tau)), \tau) \quad \tau \in [t, T] \quad (8)$$

is an optimal solution for problem (3). Furthermore, the corresponding optimal value is exactly  $V(t, x(t))$ .



$$V(t, x(t)) := \min_{u(\cdot)} \left[ \max_{w(\cdot)} \left[ \Psi(x(T)) + \int_t^T L(x(\tau), u(\tau), w(\tau)) d\tau \right] \right] \quad (3)$$

$$H(x, \lambda, u, w) = L(x, u, w) + \lambda^T f(x, u, w)$$

$$\hat{H}(x, \lambda) := \min_{u \in U(x)} \left[ \max_{w \in \mathbb{W}(x)} H(x, \lambda, u, w) \right]$$


**Theorem 1** (Isaacs verification theorem). If  $V(t, x)$  is a function of class  $C^1$  in  $t$  and  $x$  that satisfies the following Hamilton Jacobi Equation with boundary condition:

$$V_t + \hat{H}(x, V_x, t) = 0, \quad V(T, x) = \Psi(x), \quad (7)$$

where  $\hat{H}$  is given by (6), then the control strategy

$$u(\tau, x(\tau)) = \hat{u}(x(\tau), V_x(\tau, x(\tau)), \tau) \quad \tau \in [t, T] \quad (8)$$

is an optimal solution for problem (3). Furthermore, the corresponding optimal value is exactly  $V(t, x(t))$ .



$$V(t, x(t)) := \min_{u(\cdot)} \left[ \max_{w(\cdot)} \left[ \Psi(x(T)) + \int_t^T L(x(\tau), u(\tau), w(\tau)) d\tau \right] \right] \quad (3)$$

For all  $w(\cdot)$ , one has:

$$\Psi(x(T)) + \int_t^T L(x(\tau), \hat{u}(\tau, x(\tau)), w(\tau)) d\tau \leq V(t, x(t))$$


**Theorem 1** (Isaacs verification theorem). If  $V(t, x)$  is a function of class  $C^1$  in  $t$  and  $x$  that satisfies the following Hamilton Jacobi Equation with boundary condition:

$$V_t + \hat{H}(x, V_x, t) = 0, \quad V(T, x) = \Psi(x), \quad (7)$$

where  $\hat{H}$  is given by (6), then the control strategy

$$u(\tau, x(\tau)) = \hat{u}(x(\tau), V_x(\tau, x(\tau)), \tau) \quad \tau \in [t, T] \quad (8)$$

is an optimal solution for problem (3). Furthermore, the corresponding optimal value is exactly  $V(t, x(t))$ .



$$V(t, x(t)) := \min_{u(\cdot)} \left[ \max_{w(\cdot)} \left[ \Psi(x(T)) + \int_t^T L(x(\tau), u(\tau), w(\tau)) d\tau \right] \right] \quad (3)$$

taking  $\Psi(x) = p$  and  $L = -\gamma \|w - w^{nom}\|^2$ :

$$\Psi(x(T)) + \int_t^T L(x(\tau), \hat{u}(\tau, x(\tau)), w(\tau)) d\tau \leq V(t, x(t))$$


**Theorem 1** (Isaacs verification theorem). If  $V(t, x)$  is a function of class  $C^1$  in  $t$  and  $x$  that satisfies the following Hamilton Jacobi Equation with boundary condition:

$$V_t + \hat{H}(x, V_x, t) = 0, \quad V(T, x) = \Psi(x), \quad (7)$$

where  $\hat{H}$  is given by (6), then the control strategy

$$u(\tau, x(\tau)) = \hat{u}(x(\tau), V_x(\tau, x(\tau)), \tau) \quad \tau \in [t, T] \quad (8)$$

is an optimal solution for problem (3). Furthermore, the corresponding optimal value is exactly  $V(t, x(t))$ .



$$V(t, x(t)) := \min_{u(\cdot)} \left[ \max_{w(\cdot)} \left[ \Psi(x(T)) + \int_t^T L(x(\tau), u(\tau), w(\tau)) d\tau \right] \right] \quad (3)$$

taking  $\Psi(x) = p$  and  $L = -\gamma \|w - w^{nom}\|^2$ :

$$p(T) - \gamma \int_t^T \|w(\tau) - w^{nom}\|^2 d\tau \leq V(t, x(t))$$


**Theorem 1** (Isaacs verification theorem). If  $V(t, x)$  is a function of class  $C^1$  in  $t$  and  $x$  that satisfies the following Hamilton Jacobi Equation with boundary condition:

$$V_t + \hat{H}(x, V_x, t) = 0, \quad V(T, x) = \Psi(x), \quad (7)$$

where  $\hat{H}$  is given by (6), then the control strategy

$$u(\tau, x(\tau)) = \hat{u}(x(\tau), V_x(\tau, x(\tau)), \tau) \quad \tau \in [t, T] \quad (8)$$

is an optimal solution for problem (3). Furthermore, the corresponding optimal value is exactly  $V(t, x(t))$ .



$$V(t, x(t)) := \min_{u(\cdot)} \left[ \max_{w(\cdot)} \left[ \Psi(x(T)) + \int_t^T L(x(\tau), u(\tau), w(\tau)) d\tau \right] \right] \quad (3)$$

and since  $w = w^{nom} \cdot (1 + \eta)$

$$p(T) - \gamma \int_t^T \|w(\tau) - w^{nom}\|^2 d\tau \leq V(t, x(t))$$


**Theorem 1** (Isaacs verification theorem). If  $V(t, x)$  is a function of class  $C^1$  in  $t$  and  $x$  that satisfies the following Hamilton Jacobi Equation with boundary condition:

$$V_t + \hat{H}(x, V_x, t) = 0, \quad V(T, x) = \Psi(x), \quad (7)$$

where  $\hat{H}$  is given by (6), then the control strategy

$$u(\tau, x(\tau)) = \hat{u}(x(\tau), V_x(\tau, x(\tau)), \tau) \quad \tau \in [t, T] \quad (8)$$

is an optimal solution for problem (3). Furthermore, the corresponding optimal value is exactly  $V(t, x(t))$ .



$$V(t, x(t)) := \min_{u(\cdot)} \left[ \max_{w(\cdot)} \left[ \Psi(x(T)) + \int_t^T L(x(\tau), u(\tau), w(\tau)) d\tau \right] \right] \quad (3)$$

and since  $w = w^{nom} \cdot (1 + \eta)$

$$p(T) \leq \gamma \cdot T \cdot \|\eta\|^2 + V(t, x(t))$$


**Theorem 1** (Isaacs verification theorem). If  $V(t, x)$  is a function of class  $C^1$  in  $t$  and  $x$  that satisfies the following Hamilton Jacobi Equation with boundary condition:

$$V_t + \hat{H}(x, V_x, t) = 0, \quad V(T, x) = \Psi(x), \quad (7)$$

where  $\hat{H}$  is given by (6), then the control strategy

$$u(\tau, x(\tau)) = \hat{u}(x(\tau), V_x(\tau, x(\tau)), \tau) \quad \tau \in [t, T] \quad (8)$$

is an optimal solution for problem (3). Furthermore, the corresponding optimal value is exactly  $V(t, x(t))$ .



$$V(t, x(t)) := \min_{u(\cdot)} \left[ \max_{w(\cdot)} \left[ \Psi(x(T)) + \int_t^T L(x(\tau), u(\tau), w(\tau)) d\tau \right] \right] \quad (3)$$

Defining  $\theta^{opt}(x(t)) := p(T)/p(t)$ ,

$$p(T) \leq \gamma \cdot T \cdot \|\eta\|^2 + V(t, x(t))$$


**Theorem 1** (Isaacs verification theorem). If  $V(t, x)$  is a function of class  $C^1$  in  $t$  and  $x$  that satisfies the following Hamilton Jacobi Equation with boundary condition:

$$V_t + \hat{H}(x, V_x, t) = 0, \quad V(T, x) = \Psi(x), \quad (7)$$

where  $\hat{H}$  is given by (6), then the control strategy

$$u(\tau, x(\tau)) = \hat{u}(x(\tau), V_x(\tau, x(\tau)), \tau) \quad \tau \in [t, T] \quad (8)$$

is an optimal solution for problem (3). Furthermore, the corresponding optimal value is exactly  $V(t, x(t))$ .





$$V(t, x(t)) := \min_{u(\cdot)} \left[ \max_{w(\cdot)} \left[ \Psi(x(T)) + \int_t^T L(x(\tau), u(\tau), w(\tau)) d\tau \right] \right] \quad (3)$$

Defining  $\theta^{opt}(x(t)) := p(T)/p(t)$ , it comes

$$\theta^{opt}(x(t)) := \frac{p(T)}{p(t)} \leq \frac{\gamma \cdot T \cdot \|\eta\|^2 + V(t, x(t))}{p(t)}$$

$$\theta^{opt}(x(t)) := \frac{p(T)}{p(t)} \leq \frac{\gamma \cdot T \cdot \|\eta\|^2 + V(t, x(t))}{p(t)}$$



↳ Guaranteed Tumor Contraction



$$\theta^{opt}(x(t)) := \frac{p(T)}{p(t)} \leq \frac{\gamma \cdot T \cdot \|\eta\|^2 + V(t, x(t))}{p(t)}$$

Initial tumor size

Guaranteed Tumor Contraction





# The Hamilton-Jacobi-Isaacs PDE's

Solution of the  
HJI PDE's

$$\theta^{opt}(x(t)) := \frac{p(T)}{p(t)} \leq \frac{\gamma \cdot T \cdot \|\eta\|^2 + V(t, x(t))}{p(t)}$$

Initial tumor size

Guaranteed Tumor Contraction





Therapy duration

Solution of the HJI PDE's

$$\theta^{opt}(x(t)) := \frac{p(T)}{p(t)} \leq \frac{\gamma \cdot T \cdot \|\eta\|^2 + V(t, x(t))}{p(t)}$$

Initial tumor size

Guaranteed Tumor Contraction





# The Hamilton-Jacobi-Isaacs PDE's

Therapy duration  
 Relative uncertainty level  
 Solution of the HJI PDE's

$$\theta^{opt}(x(t)) := \frac{p(T)}{p(t)} \leq \frac{\gamma \cdot T \cdot \|\eta\|^2 + V(t, x(t))}{p(t)}$$

Initial tumor size

Guaranteed Tumor Contraction



$$\frac{\partial V}{\partial t}(t, x) + \hat{H}\left(x, \frac{\partial V}{\partial x}(t, x)\right) = 0 \quad ; \quad V(T, x) = \Psi(x)$$

- **Nonlinear** PDE's
- **Exponential Complexity** in the state dimension
- Only **approximate** solutions over bounded regions can be obtained
- Equivalent to the Differential Riccati Equation (DRE) for
  - ① Unconstrained,
  - ② Linear Models
  - ③ with Quadratic Cost

*Beard, R. W. and McLain, G. N. Successive Galerkin approximation . . . .*

**Int. J. of Control, (71), 5, (1997)**

*Alamir, M. Solutions of Nonlinear Optimal and Robust Control . . . .*

**Automatica, (37) (2001)**

Some features of the algorithm:

- PDE's  $\rightarrow$  ODE's
- Backward Integration
- Stabilization & Post Stabilization
- Relevance Indicator  $K\tilde{V}_{n+1}$

### Algorithm

- (1) Choose a complete set of  $C^1$  basis functions  $(\phi_i(x))_{i=1}^N$ .
- (2) Choose a sufficiently high  $N \in \mathbb{N}$ .
- (3) Choose a fixed set of collocation points  $(x^i)_{i=1}^N$  that contains a regular set w.r.t  $(\phi_i(x))_{i=1}^N$ .
- (4) Compute
  - (a)  $M$  according to (11).
  - (b)  $\Sigma := M(M^T M)^{-1} M^T$ .
  - (c)  $L = I - \Sigma$  [see (25)].
  - (d)  $K = L^T Q$  where  $Q$  is a solution of the linear system  $(LL^T)Q = L$  (see Proposition 1).
- (5) Choose sufficiently high  $\alpha > 0$ , a sampling period  $k > 0$ , a small parameter  $\varepsilon > 0$  and  $T \in \mathbb{R}_+ \cup \{\infty\}$ .
- (6)  $n = 0$ ;  $\bar{V}_n = \bar{P}$ .
- (7) Compute  $\tilde{V}_{n+1}$  solution at  $k$  of [see (18a)]
 
$$\dot{V}(\tau) = -\Gamma(T - \tau, \bar{V}) - \alpha K \bar{V}(\tau); \quad \bar{V}(0) = \bar{V}_n.$$
- (8)  $\bar{V}_{n+1} = (I - K)\tilde{V}_{n+1}$  [see (18b)].
- (9) If  $(nk \geq T)$  OR  $(\|\tilde{V}_n\|_\infty \leq \varepsilon)$  Then STOP Else  $n = n + 1$ , GOTO Step 7.
- (10) The approximate solution is given by
 
$$V(t, x) \approx [\Phi_n^T(x)[M^T M]^{-1} M^T] \bar{V}_{n+1}(t). \quad (26)$$

4.2. Some convergence results

Alamir, M. Solutions of Nonlinear Optimal and Robust Control ...

Automatica, (37) (2001)

Some features of the algorithm:

- PDE's  $\rightarrow$  ODE's
- Backward Integration
- Stabilization & Post Stabilization
- Relevance Indicator  $K\tilde{V}_{n+1}$

$$V(x) = 1.9123x_1^2 - 0.8284x_1x_2 + 1.3522x_2^2 \\ - 0.8284x_1^4 + 2.7044x_1^3x_2 + 1.3522x_1^6$$

## Algorithm

- (1) Choose a complete set of  $C^1$  basis functions  $(\phi_i(x))_{i=1}^N$ .
- (2) Choose a sufficiently high  $N \in \mathbb{N}$ .
- (3) Choose a fixed set of collocation points  $(x^i)_{i=1}^N$  that contains a regular set w.r.t  $(\phi_i(x))_{i=1}^N$ .
- (4) Compute
  - (a)  $M$  according to (11),
  - (b)  $\Sigma := M(M^T M)^{-1} M^T$ ,
  - (c)  $L = I - \Sigma$  [see (25)],
  - (d)  $K = L^T Q$  where  $Q$  is a solution of the linear system  $(LL^T)Q = L$  (see Proposition 1).
- (5) Choose sufficiently high  $\alpha > 0$ , a sampling period  $k > 0$ , a small parameter  $\varepsilon > 0$  and  $T \in \mathbb{R}_+ \cup \{\infty\}$ .
- (6)  $n = 0$ ;  $\tilde{V}_n = \tilde{P}$ .
- (7) Compute  $\tilde{V}_{n+1}$  solution at  $k$  of [see (18a)]
 
$$\dot{\tilde{V}}(\tau) = -\Gamma(T - \tau, \tilde{V}) - \alpha K \tilde{V}(\tau); \quad \tilde{V}(0) = \tilde{V}_n.$$
- (8)  $\tilde{V}_{n+1} = (I - K)\tilde{V}_{n+1}$  [see (18b)].
- (9) If  $(nk \geq T)$  OR  $(\|\tilde{V}_n\|_\infty \leq \varepsilon)$  Then STOP Else  $n = n + 1$ , GOTO Step 7.
- (10) The approximate solution is given by
 
$$V(t, x) \approx [\Phi_n^T(x)[M^T M]^{-1} M^T] \tilde{V}_{n+1}(t). \quad (26)$$

4.2. Some convergence results

Alamir, M. Solutions of Nonlinear Optimal and Robust Control ...

Automatica, (37) (2001)

Some features of the algorithm:

- PDE's  $\rightarrow$  ODE's
- Backward Integration
- Stabilization & Post Stabilization
- Relevance Indicator  $K\tilde{V}_{n+1}$

$$V_{28}(x) = 1.9067x_1^2 - 0.8223x_1x_2 + 1.3480x_2^2 \\ - 0.8223x_1^4 + 2.6961x_1^3x_2 + 1.3480x_1^6$$

## Algorithm

- (1) Choose a complete set of  $C^1$  basis functions  $(\phi_i(x))_{i=1}^N$ .
- (2) Choose a sufficiently high  $N \in \mathbb{N}$ .
- (3) Choose a fixed set of collocation points  $(x^i)_{i=1}^N$  that contains a regular set w.r.t  $(\phi_i(x))_{i=1}^N$ .
- (4) Compute
  - (a)  $M$  according to (11).
  - (b)  $\Sigma := M(M^T M)^{-1} M^T$ .
  - (c)  $L = I - \Sigma$  [see (25)].
  - (d)  $K = L^T Q$  where  $Q$  is a solution of the linear system  $(LL^T)Q = L$  (see Proposition 1).
- (5) Choose sufficiently high  $\alpha > 0$ , a sampling period  $k > 0$ , a small parameter  $\varepsilon > 0$  and  $T \in \mathbb{R}_+ \cup \{\infty\}$ .
- (6)  $n = 0$ ;  $\tilde{V}_n = \tilde{P}$ .
- (7) Compute  $\tilde{V}_{n+1}$  solution at  $k$  of [see (18a)]
 
$$\dot{\tilde{V}}(\tau) = -\Gamma(T - \tau, \tilde{V}) - \alpha K \tilde{V}(\tau); \quad \tilde{V}(0) = \tilde{V}_n.$$
- (8)  $\tilde{V}_{n+1} = (I - K)\tilde{V}_{n+1}$  [see (18b)].
- (9) If  $(nk \geq T)$  OR  $(\|\tilde{V}_n\|_\infty \leq \varepsilon)$  Then STOP Else  $n = n + 1$ , GOTO Step 7.
- (10) The approximate solution is given by
 
$$V(t, x) \approx [\Phi_n^T(x)[M^T M]^{-1} M^T] \tilde{V}_{n+1}(t). \quad (26)$$

4.2. Some convergence results

Alamir, M. Solutions of Nonlinear Optimal and Robust Control ...

Automatica, (37) (2001)

Some features of the algorithm:

- PDE's  $\rightarrow$  ODE's
- Backward Integration
- Stabilization & Post Stabilization
- Relevance Indicator  $K\tilde{V}_{n+1}$

Table 1  
 Convergence result for Example 5.1 (execution time  $\approx 5$  s)

$t = nk$	$\ \tilde{V}\ _\infty$	$\ \dot{\tilde{V}}\ _\infty$	$\ K\tilde{V}\ _\infty$
0.25	0.46	1.79	8.61E-07
1.00	1.49	0.88	7.70E-06
2.00	1.94	0.37	5.65E-06
3.00	2.08	0.10	2.45E-06
4.00	2.12	2.18E-02	8.40E-07
4.75	2.13	1.06E-02	5.29E-07

## Algorithm

- (1) Choose a complete set of  $C^1$  basis functions  $(\phi_i(x))_{i=1}^N$ .
- (2) Choose a sufficiently high  $N \in \mathbb{N}$ .
- (3) Choose a fixed set of collocation points  $(x^i)_{i=1}^N$  that contains a regular set w.r.t  $(\phi_i(x))_{i=1}^N$ .
- (4) Compute
  - (a)  $M$  according to (11).
  - (b)  $\Sigma := M(M^T M)^{-1} M^T$ .
  - (c)  $L = I - \Sigma$  [see (25)].
  - (d)  $K = L^T Q$  where  $Q$  is a solution of the linear system  $(LL^T)Q = L$  (see Proposition 1).
- (5) Choose sufficiently high  $\alpha > 0$ , a sampling period  $k > 0$ , a small parameter  $\varepsilon > 0$  and  $T \in \mathbb{R}_+ \cup \{\infty\}$ .
- (6)  $n = 0$ ;  $\tilde{V}_n = \tilde{P}$ .
- (7) Compute  $\tilde{V}_{n+1}$  solution at  $k$  of [see (18a)]
 
$$\dot{\tilde{V}}(\tau) = -\tilde{F}(T - \tau, \tilde{V}) - \alpha K \tilde{V}(\tau); \quad \tilde{V}(0) = \tilde{V}_n.$$
- (8)  $\tilde{V}_{n+1} = (I - K)\tilde{V}_{n+1}$  [see (18b)].
- (9) If  $(nk \geq T)$  OR  $(\|\tilde{V}_n\|_\infty \leq \varepsilon)$  Then STOP Else  $n = n + 1$ , GOTO Step 7.
- (10) The approximate solution is given by
 
$$V(t, x) \approx [\Phi_N^T(x)[M^T M]^{-1} M^T] \tilde{V}_{n+1}(t). \quad (26)$$

4.2. Some convergence results

Alamir, M. Solutions of Nonlinear Optimal and Robust Control ...

Automatica, (37) (2001)

## Cost Function

$$\min_{v \in [0, v^{max}]^{[0, T]}} \max_{w \in [\mathbb{R}^{n_w}]^{[0, T]}} J(x_0, v(\cdot), w(\cdot)) := p(T) + \int_0^T \left[ \|v(\tau)\|_R^2 - \|w(\tau) - w^{nom}\|_W^2 \right] d\tau$$

$$W^{\frac{1}{2}} := \gamma^{\frac{1}{2}} \cdot \text{diag}\left(\frac{1}{w_1^{nom}}, \dots, \frac{1}{w_{n_w}^{nom}}\right)$$

## Constraints

- $v_i \in [0, v_i^{max}]$ ,  $i \in \{1, 2\}$
- For  $i \in \{1, 2\}$ ,

$$\int_0^T v_i(\tau) d\tau = y_i(T) \leq y_i^{max}$$

## Disturbance set

$$\mathbb{W} := \left\{ w \mid w_i = w^{nom}(1 + \eta_i) \right\}$$

$$\begin{aligned} \dot{p} &= -w_1 p \ln\left(\frac{p}{q}\right) - w_2 p v_2 \\ \dot{q} &= w_3 p - (w_4 + w_5 p^{\frac{2}{3}})q - w_6 v_1 q \\ \dot{y}_1 &= v_1 \\ \dot{y}_2 &= v_2 \end{aligned}$$

*Hahnfeldt et al.* Tumor development under angiogenic signaling: ...

*Cancer Research*, (59), 1999.

- $p$  tumor cells population level
- $q$  vasculature level
- $u_1$  Anti-angiogenic drug
- $v_1$  Chemotherapy drug
- $v_2, y_2$  Already injected drug
- $w \in \mathbb{R}^6$  model parameters

## Cost Function

$$\min_{v \in [0, v^{max}]^{[0, T]}} \max_{w \in [\mathbb{R}^{n_w}]^{[0, T]}} J(x_0, v(\cdot), w(\cdot)) := p(T) + \int_0^T \left[ \|v(\tau)\|_R^2 - \|w(\tau) - w^{nom}\|_W^2 \right] d\tau$$

$$W^{\frac{1}{2}} := \gamma^{\frac{1}{2}} \cdot \text{diag}\left(\frac{1}{w_1^{nom}}, \dots, \frac{1}{w_{n_w}^{nom}}\right)$$

## Constraints

- $v_i \in [0, v_i^{max}]$ ,  $i \in \{1, 2\}$
- For  $i \in \{1, 2\}$ ,

$$\int_0^T v_i(\tau) d\tau = y_i(T) \leq y_i^{max}$$

## Disturbance set

$$\mathbb{W} := \left\{ w \mid w_i = w^{nom}(1 + \eta_i) \right\}$$

$$\begin{aligned} \dot{p} &= -w_1 p \ln\left(\frac{p}{q}\right) - w_2 p v_2 \\ \dot{q} &= w_3 p - (w_4 + w_5 p^{\frac{2}{3}})q - w_6 v_1 q \\ \dot{y}_1 &= v_1 \\ \dot{y}_2 &= v_2 \end{aligned}$$

*Hahnfeldt et al.* Tumor development under angiogenic signaling: ...

*Cancer Research*, (59), 1999.

- $p$  tumor cells population level
- $q$  vasculature level
- $u_1$  Anti-angiogenic drug
- $v_1$  Chemotherapy drug
- $v_2, y_2$  Already injected drug
- $w \in \mathbb{R}^6$  model parameters

Normalized State Variable:


$$x = \left( \frac{p}{p^{max}} \quad \frac{q}{q^{max}} \quad \frac{y_1}{y_1^{max}} \quad \frac{y_2}{y_2^{max}} \right)^T \in \mathbb{R}^4$$

Change in the control variable:

$$v_i(t) = S(y_i(t)/y_i^{max}) \cdot u_i(t)$$

where  $S(r) \in [0, 1[$  is given by:

$$S(r) = \max\{-\tanh(\beta_s(r - 1)), 0\}$$



$$\begin{aligned} \dot{p} &= -w_1 p \ln\left(\frac{p}{q}\right) - w_2 p v_2 \\ \dot{q} &= w_3 p - (w_4 + w_5 p^{\frac{2}{3}})q - w_6 v_1 q \\ \dot{y}_1 &= v_1 \\ \dot{y}_2 &= v_2 \end{aligned}$$

*Hahnfeldt et al.* Tumor development under angiogenic signaling: ...

**Cancer Research**, (59), 1999.

- $p$  tumor cells population level
- $q$  vasculature level
- $u_1$  Anti-angiogenic drug
- $v_1$  Chemotherapy drug
- $v_2, y_2$  Already injected drug
- $w \in \mathbb{R}^6$  model parameters

Normalized State Variable:


$$x = \left( \frac{p}{p^{max}} \quad \frac{q}{q^{max}} \quad \frac{y_1}{y_1^{max}} \quad \frac{y_2}{y_2^{max}} \right)^T \in \mathbb{R}^4$$

Change in the control variable:

$$v_i(t) = S(y_i(t)/y_i^{max}) \cdot u_i(t)$$

where  $S(r) \in [0, 1[$  is given by:

$$S(r) = \max\{-\tanh(\beta_s(r - 1)), 0\}$$



$$\begin{aligned} \dot{p} &= -w_1 p \ln\left(\frac{p}{q}\right) - w_2 p v_2 \\ \dot{q} &= w_3 p - (w_4 + w_5 p^{\frac{2}{3}})q - w_6 v_1 q \\ \dot{y}_1 &= v_1 \\ \dot{y}_2 &= v_2 \end{aligned}$$

*Hahnfeldt et al.* Tumor development under angiogenic signaling: ...**Cancer Research, (59), 1999.**

$$f(x, u, w) := \begin{pmatrix} -w_1 x_1 \ln(\alpha x_1/x_2) - w_2 x_1 S(x_4) u_2 \\ \alpha w_3 x_1 - (w_4 + \beta w_5 x_1^{2/3}) x_2 - w_6 x_2 S(x_3) u_1 \\ \varrho_1 \cdot S(x_3) u_1 \\ \varrho_2 \cdot S(x_4) u_2 \end{pmatrix}$$

where  $\alpha, \beta, \sigma$  and  $\varrho_i$  are positive constant given by:

$$\alpha := \frac{p^{max}}{q^{max}} ; \beta := (p^{max})^{\frac{2}{3}} ; \sigma := \frac{1}{q^{max}} ; \varrho_i := \frac{1}{y_i^{max}}$$

## System Model

$$f(x, u, w) := \begin{pmatrix} -w_1 x_1 \ln(\alpha x_1 / x_2) - w_2 x_1 S(x_4) u_2 \\ \alpha w_3 x_1 - (w_4 + \beta w_5 x_1^{2/3}) x_2 - w_6 x_2 S(x_3) u_1 \\ \varrho_1 \cdot S(x_3) u_1 \\ \varrho_2 \cdot S(x_4) u_2 \end{pmatrix}$$

## Cost Function

$$\Psi(x) = x_1$$

$$L(x, u, w) := u^T R u - \|w - w^{nom}\|_W^2$$

## The Hamiltonian

$$H(x, u, w) = u^T R u - \|w - w^{nom}\|_W^2 + \lambda^T (F_0(x) + F_1(x) u_1 + F_2(x) u_2)^T w + \lambda^T F_3(x) u$$

## System Model

$$f(x, u, w) := \begin{pmatrix} -w_1 x_1 \ln(\alpha x_1 / x_2) - w_2 x_1 S(x_4) u_2 \\ \alpha w_3 x_1 - (w_4 + \beta w_5 x_1^{2/3}) x_2 - w_6 x_2 S(x_3) u_1 \\ \varrho_1 \cdot S(x_3) u_1 \\ \varrho_2 \cdot S(x_4) u_2 \end{pmatrix}$$

$$F_0(x) := \begin{pmatrix} -x_1 \ln(\alpha x_1 / x_2) & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 \\ 0 & \alpha x_1 & 0 & 0 \\ 0 & -x_2 & 0 & 0 \\ 0 & -\beta x_1^{2/3} x_2 & 0 & 0 \\ 0 & 0 & 0 & 0 \end{pmatrix}$$

## Cost Function

$$\Psi(x) = x_1$$

$$L(x, u, w) := u^T R u - \|w - w^{nom}\|_W^2$$

$$F_1(x), F_2(x) :=$$

$$\begin{pmatrix} 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 \\ 0 & -x_2 S(x_3) & 0 & 0 \end{pmatrix}, \begin{pmatrix} 0 & 0 & 0 & 0 \\ -x_1 S(x_4) & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 \end{pmatrix}$$

## The Hamiltonian

$$H(x, u, w) = u^T R u - \|w - w^{nom}\|_W^2 + \lambda^T (F_0(x) + F_1(x) u_1 + F_2(x) u_2)^T w + \lambda^T F_3(x) u$$

$$F_3(x) := \begin{pmatrix} 0 & 0 \\ 0 & 0 \\ \varrho_1 S(x_3) & 0 \\ 0 & \varrho_2 S(x_4) \end{pmatrix}$$

## System Model

$$f(x, u, w) := \begin{pmatrix} -w_1 x_1 \ln(\alpha x_1 / x_2) - w_2 x_1 S(x_4) u_2 \\ \alpha w_3 x_1 - (w_4 + \beta w_5 x_1^{2/3}) x_2 - w_6 x_2 S(x_3) u_1 \\ \varrho_1 \cdot S(x_3) u_1 \\ \varrho_2 \cdot S(x_4) u_2 \end{pmatrix}$$

## Cost Function

$$\Psi(x) = x_1$$

$$L(x, u, w) := u^T R u - \|w - w^{nom}\|_W^2$$

## The Hamiltonian

$$H(x, u, w) = u^T R u - \|w - w^{nom}\|_W^2 + \lambda^T (F_0(x) + F_1(x) u_1 + F_2(x) u_2)^T w + \lambda^T F_3(x) u$$

## Optimal Game Feedback Strategies:

$$\hat{u}(x, \lambda) := \min_{u \in [0, u^{max}]} \frac{1}{2} u^T [\mathcal{R}(x, \lambda)] u + [f(x, \lambda)] u \quad (29)$$

$$\hat{w}(x, \lambda) := w^{nom} + \frac{1}{2} W^{-1} [\Theta_0(x, \lambda) + \Theta_1(x, \lambda) \hat{u}(x, \lambda)] \quad (30)$$

where

$$\mathcal{R}(x, \lambda) := 2R + \frac{1}{2} \Theta_1^T(x, \lambda) W^{-1} \Theta_1(x, \lambda) \quad (31)$$

$$f(x, \lambda) := \frac{1}{2} \Theta_0^T(x, \lambda) W^{-1} \Theta_1(x, \lambda) + \frac{1}{2} (w^{nom})^T \Theta_1(x, \lambda) + \lambda^T F_3(x) \quad (32)$$

$$\Theta_0(x, \lambda) := F_0(x) \lambda \quad (33)$$

$$\Theta_1(x, \lambda) := [F_1(x) \lambda, F_2(x) \lambda] \quad (34)$$


## Numerical Solution parameters:

- $T \in [0, 1]$
- $\gamma = 0.05$
- $N = 15$  (quadratic approximation)
- $n_p = 5^4 = 625$
- $y_i^{max} \in \{0.5, 1\}$
- $\eta_i \in \{15\%, 30\%, 35\%\}$
- $p^{max} = q^{max} = 2 \times 10^4$

## Simulations aim at investigating the impact of:


- The drug available quantities
- The treatment duration
- The initial condition  $(p, q)$

## Constrained Robust Combined Therapy



achievable performance as a function of the normalized initial state  $(p, q, 0, 0)$  with the integral constraints defined by  $y_1^{\max} = y_2^{\max} = 1$  and a treatment duration  $T = 1$ .  
 Left: optimal cost  $J^{opt}$ , Center: guaranteed contraction factor  $\theta^{opt}$ , Right: contour lines for  $\theta^{opt}$ .


## Constrained Robust Combined Therapy



achievable performance as a function of the normalized initial state  $(p, q, 0, 0)$  with the integral constraints defined by  $y_1^{\max} = y_2^{\max} = 0.5$  and a treatment duration  $T = 1$ .


Left: optimal cost  $J^{opt}$ , Center: guaranteed contraction factor  $\theta^{opt}$ , Right: contour lines for  $\theta^{opt}$ .

## Constrained Robust Combined Therapy



achievable performance as a function of the normalized initial state  $(p, q, 0, 0)$  with the integral constraints defined by  $y_1^{max} = y_2^{max} = 1$  and a treatment duration  $T = 1$ .  
 Left: optimal cost  $J^{opt}$ , Center: guaranteed contraction factor  $\theta^{opt}$ , Right: contour lines for  $\theta^{opt}$ .



## Constrained Robust Combined Therapy



achievable performance as a function of the normalized initial state  $(p, q, 0, 0)$  with the integral constraints defined by  $y_1^{max} = y_2^{max} = 1$  and a treatment duration  $\mathbf{T} = 2$ .



Left: optimal cost  $J^{opt}$ , Center: guaranteed contraction factor  $\theta^{opt}$ , Right: contour lines for  $\theta^{opt}$ .

## Constrained Robust Combined Therapy



The state feedback map  $u = K(0, x)$  for  $x = (p, q, 0, 0)^T$  obtained when the integral saturations  $y_1^{max} = y_2^{max} = 1$  is used together with the treatment duration  $T = 1$

## Constrained Robust Combined Therapy



The state feedback map  $u = K(0, x)$  for  $x = (p, q, 0, 0)^T$  obtained when the integral saturations  $y_1^{max} = y_2^{max} = 1$  is used together with the treatment duration  $T = 2$

For further details

M. Alamir, *Robust Feedback Design For Combined Therapy of Cancer. Optimal Control, Applications and Methods. (To Appear 2013).*

## Conclusion & Future Work

- **Systematic** approach to address **relevant problems**

## Conclusion & Future Work

- **Systematic** approach to address **relevant problems**
- → Off-Line Computable **Closed-Form** Feedback Strategy

## Conclusion & Future Work

- **Systematic** approach to address **relevant problems**
- → Off-Line Computable **Closed-Form** Feedback Strategy
- Can be used to compute **state-dependent sensitivity** maps:

$$\frac{\partial \theta^{opt}(x)}{\partial \eta_i} \quad \text{and/or} \quad \frac{\partial \theta^{opt}(x)}{\partial y_j^{max}} \quad \text{and/or} \quad \frac{\partial \theta^{opt}(x)}{\partial T}$$

---

## Conclusion & Future Work

- **Systematic** approach to address **relevant problems**
- → Off-Line Computable **Closed-Form** Feedback Strategy
- Can be used to compute **state-dependent sensitivity** maps:

$$\frac{\partial \theta^{opt}(x)}{\partial \eta_i} \quad \text{and/or} \quad \frac{\partial \theta^{opt}(x)}{\partial y_j^{max}} \quad \text{and/or} \quad \frac{\partial \theta^{opt}(x)}{\partial T}$$

- 
- Apply to **different models/therapies** of cancer/HIV

- **Systematic** approach to address **relevant problems**
- → Off-Line Computable **Closed-Form** Feedback Strategy
- Can be used to compute **state-dependent sensitivity** maps:

$$\frac{\partial \theta^{opt}(x)}{\partial \eta_i} \quad \text{and/or} \quad \frac{\partial \theta^{opt}(x)}{\partial y_j^{max}} \quad \text{and/or} \quad \frac{\partial \theta^{opt}(x)}{\partial T}$$

- 
- Apply to **different models/therapies** of cancer/HIV
  - **Model reduction** (part of the state → disturbance  $w$ )

$$\dot{x} = f_1(x, z, u), \quad \dot{z} = f_2(x, z, u)$$

$$\rightarrow \dot{x} = f_1(x, w, u) \quad \text{with} \quad w(t) \in [z_{min}(t), z_{max}(t)]$$

- **Systematic** approach to address **relevant problems**
- → Off-Line Computable **Closed-Form** Feedback Strategy
- Can be used to compute **state-dependent sensitivity** maps:

$$\frac{\partial \theta^{opt}(x)}{\partial \eta_i} \quad \text{and/or} \quad \frac{\partial \theta^{opt}(x)}{\partial y_j^{max}} \quad \text{and/or} \quad \frac{\partial \theta^{opt}(x)}{\partial T}$$

- 
- Apply to **different models/therapies** of cancer/HIV
  - **Model reduction** (part of the state → disturbance  $w$ )

$$\dot{x} = f_1(x, z, u), \quad \dot{z} = f_2(x, z, u)$$

$$\rightarrow \dot{x} = f_1(x, w, u) \quad \text{with} \quad w(t) \in [z_{min}(t), z_{max}(t)]$$

- **Unstructured Model Identification**

$$\dot{x} = f(t, x, p) \quad \text{with} \quad p = K_M(x) \quad \text{and} \quad y = h(x)$$

$$\text{HJB} \rightarrow p = K(t, x(t)) \quad \text{gives insight on} \quad K_M(x)$$

of the treatment and neglected the issue of patient variability during the treatment course. Without such a strategy, any change in patient parameters may lead to sub-optimal treatment and poor patient outcomes. Very few works (Chareyron and Alamir, 2009; Florian et al., 2008) have examined this issue. These works cast the

*K. L. Kiran & S. Lakshminarayanan,  
Global Sensitivity Analysis and Model-Based Reactive Scheduling of Targeted Cancer  
Immunotherapy. **BioSystems**, (101), 2010.*

